Login

Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Growth Factors, Cytokines » Growth Factors-Other » DMC, Recombinant, Human (Dendritic cell and Monocyte Chemokine-like Protein, VEGF Co-regulated Chemokine 1, VCC1) (BSA Free)

DMC, Recombinant, Human (Dendritic cell and Monocyte Chemokine-like Protein, VEGF
Co-regulated Chemokine 1, VCC1) (BSA Free)

Pricing

  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.

Specifications

Dendritic cell and monocyte chemokine-like protein (DMC), also known as VEGF-correlated chemokine-1 (VCC-1), is a secreted molecule with a size and predicted three-dimensional folding pattern similar to that of chemokines CXCL8/IL-8 and CXCL14/BRAK (1, 2). It has no predicted N-glycosylation site. Cleavage of a 23 amino acid (aa) signal sequence yields the mature 96 aa human DMC. DMC is constitutively produced by airway and intestinal epithelium (1). It induces the chemotaxis of quiescent, but not LPS-activated peripheral blood monocytes and dendritic cells (1). DMC expression is increased in endothelial cells when they are induced to form tubes in vitro (2). Transgenic overexpression in NIH3T3 cells causes upregulation of proteins such as VEGF and FGF basic, and increases cell growth rate and tumorigenicity (2). DMC, plus two other chemokines that play roles in angiogenesis, CXCL1/GRO and CXCL8/IL-8, show a correlated expression pattern with VEGF in primary lung, breast and esophageal tumors (2). DMC is, therefore, suggested to play a role in tumor angiogenesis. Mature human DMC shares 73%, 71% and 64% amino acid sequence identity with bovine, mouse and rat DMC, respectively.
Catalog #D8074-90AX
SourceA DNA sequence encoding the mature human DMC (Leu 24-Leu 119; Accession # NP_940879) was expressed in E. coli.
Molecular MassThe 96 amino acid residue recombinant human DMC has a predicted molecular mass of approximately 11.3kD.
Endotoxin Level< 1.0 EU per 1 g of the protein as determined by the LAL method.
ActivityMeasured by its ability to induce VEGF expression in endothelial cells (Weinstein, E.J. et al., 2006, BBRC, 350:74). The ED50 for this effect is typically 1-5ug/ml.
RecontitutionIt is recommended that sterile PBS be added to the vial to prepare a working stock solution of no less than 100ug/ml. The carrier-free protein should be used immediately upon reconstitution to avoid losses in activity due to non-specific binding to the inside surface of the vial. For long term storage as a dilute solution, a carrier protein (e.g. 0.1% HSA or BSA) should be added to the vial.
Storage and StabilityLyophilized samples are stable for up to twelve months at -20°C. Upon reconstitution, this protein can be stored under sterile conditions at 2-8°C for one month or at -20°C in a manual defrost freezer for three months without detectable loss of activity. Avoid repeated freeze-thaw cycles.
SourceE. coli
Purity95%, as determined by SDS-PAGE and visualized by silver stain.
ConcentrationAs reported
FormSupplied as a lyophilized powder in PBS.
Important NoteThis product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.


External Links